prikaz prve stranice dokumenta Methodology for clinical genotyping of CYP2D6 and CYP2C19
  Preuzmi
PDF 1.18 MB
Znanstveni rad - Izvorni znanstveni rad
Methodology for clinical genotyping of CYP2D6 and CYP2C19
Translational Psychiatry, 11 (2021), 1; 596. https://doi.org/10.1038/s41398-021-01717-9
Carvalho Henriques, Beatriz; Buchner, Avery; Hu, Xiuying; Wang, Yabing; Yavorskyy, Vasyl; Wallace, Keanna; Dong, Rachael; Martens, Kristina; Carr, Michael S.; Behroozi Asl, Bahareh; Hague, Joshua; Sivapalan, Sudhakar; Maier, Wolfgang; Dernovsek, Mojca Z.; Henigsberg, Neven; Hauser, Joanna; Souery, Daniel; Cattaneo, Annamaria; Mors, Ole; Rietschel, Marcella; Pfeffer, Gerald; Hume, Stacey; Aitchison, Katherine J. Više autora...

Citirajte ovaj rad

Carvalho Henriques, B., Buchner, A., Hu, X., Wang, Y., Yavorskyy, V., Wallace, K. ... Aitchison, K. J. (2021). Methodology for clinical genotyping of CYP2D6 and CYP2C19. Translational Psychiatry, 11. (1). doi: 10.1038/s41398-021-01717-9

Carvalho Henriques, Beatriz, et al. "Methodology for clinical genotyping of CYP2D6 and CYP2C19." Translational Psychiatry, vol. 11, br. 1, 2021. https://doi.org/10.1038/s41398-021-01717-9

Carvalho Henriques, Beatriz, Avery Buchner, Xiuying Hu, Yabing Wang, Vasyl Yavorskyy, Keanna Wallace, Rachael Dong, et al. "Methodology for clinical genotyping of CYP2D6 and CYP2C19." Translational Psychiatry 11, br. 1 (2021). https://doi.org/10.1038/s41398-021-01717-9

Carvalho Henriques, B., et al. (2021) 'Methodology for clinical genotyping of CYP2D6 and CYP2C19', Translational Psychiatry, 11(1). doi: 10.1038/s41398-021-01717-9

Carvalho Henriques B, Buchner A, Hu X, Wang Y, Yavorskyy V, Wallace K, i sur.. Methodology for clinical genotyping of CYP2D6 and CYP2C19. Translational Psychiatry [Internet]. 22.11.2021. [pristupljeno 10.04.2024.];11(1). doi: 10.1038/s41398-021-01717-9

B. Carvalho Henriques, et al., "Methodology for clinical genotyping of CYP2D6 and CYP2C19", Translational Psychiatry, vol. 11, br. 1, Studeni 2021. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:591830. [Citirano: 10.04.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:591830
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Methodology for clinical genotyping of CYP2D6 and CYP2C19
AutorBeatriz Carvalho Henriques
AutorAvery Buchner
AutorXiuying Hu
AutorYabing Wang
AutorVasyl Yavorskyy
AutorKeanna Wallace
AutorRachael Dong
AutorKristina Martens
AutorMichael S. Carr
AutorBahareh Behroozi Asl
AutorJoshua Hague
AutorSudhakar Sivapalan
AutorWolfgang Maier
AutorMojca Z. Dernovsek
AutorNeven Henigsberg
AutorJoanna Hauser
AutorDaniel Souery
AutorAnnamaria Cattaneo
AutorOle Mors
AutorMarcella Rietschel
AutorGerald Pfeffer
AutorStacey Hume
AutorKatherine J. Aitchison
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA PSIHIJATRIJU I PSIHOLOŠKU MEDICINU)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Psihijatrija
Sažetak (engleski)
Many antidepressants, atomoxetine, and several antipsychotics are metabolized by the cytochrome P450 enzymes CYP2D6 and CYP2C19, and guidelines for prescribers based on genetic variants exist. Although some laboratories offer such testing, there is no consensus regarding validated methodology for clinical genotyping of CYP2D6 and CYP2C19. The aim of this paper was to cross-validate multiple technologies for genotyping CYP2D6 and CYP2C19 against each other, and to contribute to feasibility for clinical implementation by providing an enhanced range of assay options, customizable automated translation of data into haplotypes, and a workflow algorithm. AmpliChip CYP450 and some TaqMan single nucleotide variant (SNV) and copy number variant (CNV) data in the Genome-based therapeutic drugs for depression (GENDEP) study were used to select 95 samples (out of 853) to represent as broad a range of CYP2D6 and CYP2C19 genotypes as possible. These 95 included a larger range of CYP2D6 hybrid configurations than have previously been reported using inter-technology data. Genotyping techniques employed were: further TaqMan CNV and SNV assays, xTAGv3 Luminex CYP2D6 and CYP2C19, PharmacoScan, the Ion AmpliSeq Pharmacogenomics Panel, and, for samples with CYP2D6 hybrid configurations, long-range polymerase chain reactions (L-PCRs) with Sanger sequencing and Luminex. Agena MassARRAY was also used for CYP2C19. This study has led to the development of a broader range of TaqMan SNV assays, haplotype phasing methodology with TaqMan adaptable for other technologies, a multiplex genotyping method for efficient identification of some hybrid haplotypes, a customizable automated translation of SNV and CNV data into haplotypes, and a clinical workflow algorithm.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaTranslational Psychiatry
Brojčani podacivol. 11, br. 1, 596
e-ISSN2158-3188
DOIhttps://doi.org/10.1038/s41398-021-01717-9
URN:NBNurn:nbn:hr:105:591830
Datum objave publikacije2021-11-22
URL dokumentahttps://www.nature.com/articles/s41398-021-01717-9
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 4.0 međunarodna (CC BY 4.0)
Datum i vrijeme pohrane2022-03-09 09:44:55